Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergenic Products Advisory Committee meeting

Executive Summary

A proposed strategy for the reclassification of Category IIIA allergenic products - those for which data are insufficient for classification but which are thought to have a favorable risk-benefit ratio and should remain on the market pending completion of testing - will be discussed at the Sept. 13 meeting of FDA's Allergenic Products Advisory Committee. In its 2005 meeting, the committee had advised FDA to expand its data search boundaries for the reclassification of Category IIIA allergenic extracts (1"The Pink Sheet" April 11, 2005, p. 36). The meeting, to be held at the National Institutes of Health, Bethesda, Md. from noon to 3:45 p.m., will include an update of CBER's Laboratory of Immunobiochemistry's research program on parasitic and allergenic products...
Advertisement

Related Content

Allergenic Extract Data Search Parameters Should Be Widened, Cmte. Says
Allergenic Extract Data Search Parameters Should Be Widened, Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS047546

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel